echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The supplement is expected to be carried out within 2 years. There is still a chance for drugs not listed!

    The supplement is expected to be carried out within 2 years. There is still a chance for drugs not listed!

    • Last Update: 2019-11-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] the negotiation on the adjustment of the new version of the national medical insurance drug catalog has been announced to end A total of 97 drugs, including 70 new drugs, have entered the medical insurance catalogue through negotiation According to incomplete statistics in the industry, a total of 17 pharmaceutical companies have entered the medical insurance, including Hengrui, Yifan pharmaceutical, Lizhu group, etc The products of these pharmaceutical companies are listed in the medical insurance catalog, which is generally conducive to the marketing and future sales of the selected products, and has a positive impact on the company's business performance At the same time of "Congratulation" from some pharmaceutical enterprises, there are also many pharmaceutical enterprises that are not listed in the catalogue, worried that their products will lose market share However, don't worry, there will be opportunities for the future of drugs that are not listed! At the press conference on November 28, Xiong Xianjun, director of the medical service management department of the State Medical Insurance Bureau, made it clear that "the State Medical Insurance Bureau will comprehensively consider clinical needs, medical insurance affordability and the willingness of enterprises to reduce prices, and carry out the work of renegotiation" The industry believes that the negotiation result is valid within 2 years according to the validity period of the Agreement included in the medical insurance as of December 31, 2021 Therefore, the possible supplement in the future should be expected to be carried out within two years, when the pharmaceutical enterprises not listed will have the opportunity to choose again So what are the benefits of inclusion in the Medicare catalog? Why has the industry started to play games? First, the ability of "carrying goods" is stronger The sales market of products included in the price negotiation system of medical insurance is obviously larger In May 2019, according to the PDB drug comprehensive database data provided by China Pharmaceutical Industry Information Center, some enterprises made statistics on the sales of rituximab, Herceptin, avidin and Novelli, all of which are products included in the price negotiation system of medical insurance The results show that although these four products have been greatly reduced in different degrees after entering the medical insurance, with the ranges of 29%, 65%, 62% and 43% respectively, due to the large sales volume, the actual sales amount of the four products in 2018 increased by 13%, 48%, 74% and 120% respectively year on year It can also be seen from the above data that the effect of price for quantity of these products is very obvious This is also the reason why many pharmaceutical companies actively enter the medical insurance However, pharmaceutical companies are more concerned about whether the capacity can keep up after a large amount of production Second, it helps pharmaceutical companies to be recognized by the market Entering the medical insurance, pharmaceutical enterprises will also be supported and encouraged by various policies to attract the attention, attention and recognition of relevant departments of medical insurance Since 2019, driven by a series of policies such as medical insurance fee control and volume purchase, the pharmaceutical market pattern has changed, the market competition is very fierce, many small and medium-sized enterprises have been forced to withdraw from the market, and the industry trend of "the strong is always strong" is obvious In this context, the medical insurance of pharmaceutical products is undoubtedly a proof of the strength of the enterprise itself, which is expected to be more competitive in the follow-up development The author also understands that many enterprises who give up medical insurance have their own considerations, including market strategy, commercialization strategy and so on For example, in the hot PD-1 variety negotiation, MSD gave up the opportunity to enter the medical insurance This may be because MSD is in the "seller's market" and is reluctant to lower its price The industry believes that with the continuous development of domestic generic drugs and the acceleration of product substitution in the future, although multinational pharmaceutical companies have their own product advantages, but the price is expensive, most of the patients in China can't bear it With the continuous development of domestic generic drugs, high-quality products with better therapeutic effect and medical insurance may "hang" the original pharmaceutical companies.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.